News

Huntington Ingalls Industries ( NYSE: HII) shares jumped more than 5% in premarket trading Thursday after the U.S. defense ...
Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...
Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.
Amazon makes its own soundbars, and this compact bar is one of them. For under $100, you can get both DTS Virtual X and Dolby Audio, as well as a significant upgrade over standard TV audio quality ...
C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...
C3.ai Inc (AI) is winning back investors with a management shake-up that could redefine its future after CEO and founder Tom ...
This leader in cloud observability is swiftly moving into the artificial intelligence space, and it's having major success.
C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...
Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...
C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.
Jefferies warns of high attrition in TCS following the layoff debacle, while Nasscom posts an impersonal response; Tata Consultancy Services shares continue to tank, falling 25 per cent in six months ...
The all-new LG C5 OLED TV was released in March of this year, and Amazon just dropped the 55-inch model to $1,396.99 - a new ...